Vedolizumab in Indian patients with inflammatory bowel disease: final results from a prospective, multicenter, open-label, phase 4 study
Journal of Clinical and Experimental Gastroenterology · 21.03.2026 · 5 (1) · 7
DOI: 10.46439/gastro.5.029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Gastroenterology, online erschienen am 21.03.2026. Verfasst von Mayank Kabrawala und 12 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
There is limited data on the effectiveness and safety of vedolizumab for Indian patients, making this study the first focused evaluation of its use in this population.
Methods
This prospective, multicenter, open-label phase IV study enrolled patients aged 18–65 with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), who received vedolizumab 300 mg IV at weeks 0, 2, and 6 (induction) and at weeks 14, 22, 30, 38, and 46 (maintenance). The primary objective was safety; the secondary, effectiveness. Descriptive statistics were used to summarize demographic, baseline disease characteristics, prior/concomitant medications, and treatment outcomes.
Results
A total of 150 patients were enrolled (102 with UC; 48 with CD). Adverse Events (AE) affected 83 patients (55.3%), with mild AE in 72 (48%). Treatment related adverse events (TEAE) occurred in 52 (51%) patients with UC and 29 (60.4%) with CD, Serious adverse events (SAE) occurred in 8 (5.3%) patients. Additionally, 3.3% had at least 1 Adverse drug reaction (ADR), and 2.7% had adverse events of special interest (AESI). Reported ADR/AESI cases included one patient each with pulmonary tuberculosis, tuberculous pleurisy, rectal adenocarcinoma, and hypertension. Overall clinical response rates for weeks 14, 30 and 46 were 60.7%, 65.3%, and 72% and remission rates were 42%, 44%, and 53.3% respectively. Mucosal healing was observed in 18% patients at week 46 (23 (22.5%) with UC; 4 (8.3%) with CD). Quality of life scores showed improvements across both UC and CD groups, with increases noted from baseline of 5 at week 14 to 13 at week 46 in both groups.
Conclusion
This study demonstrates that vedolizumab has a good safety and effectiveness profile in Indian patients with moderate-to-severe UC or CD.
Zitieren
APA
Kabrawala, M., Banerjee, R., Ahuja, V., Kavitha, A., Bharadwaj, V., Dalal, A., Kumar, B. R., Mukewar, S., Sood, A., Prasad, V. M., Arora, S., Bahuguna, G., & Sharma, A. (2026). Vedolizumab in Indian patients with inflammatory bowel disease: final results from a prospective, multicenter, open-label, phase 4 study. Journal of Clinical and Experimental Gastroenterology, 5(1), 7. https://doi.org/10.46439/gastro.5.029
Vancouver
Kabrawala M, Banerjee R, Ahuja V, Kavitha A, Bharadwaj V, Dalal A, et al. Vedolizumab in Indian patients with inflammatory bowel disease: final results from a prospective, multicenter, open-label, phase 4 study. Journal of Clinical and Experimental Gastroenterology. 2026;5(1):7. doi:10.46439/gastro.5.029
BibTeX
@article{Kabrawala2026,
author = {Kabrawala, Mayank and Banerjee, Rupa and Ahuja, Vineet and Kavitha, Anumula and Bharadwaj, Vaishali and Dalal, Ashok and Kumar, B Ramesh and Mukewar, Shrikant and Sood, Ajit and Prasad, VG Mohan and Arora, Sandeep and Bahuguna, Gaurav and Sharma, Avi},
title = {Vedolizumab in Indian patients with inflammatory bowel disease: final results from a prospective, multicenter, open-label, phase 4 study},
journal = {Journal of Clinical and Experimental Gastroenterology},
year = {2026},
volume = {5},
number = {1},
pages = {7},
doi = {10.46439/gastro.5.029}
}
EUVIMED